|
1
|
Miller KD, Nogueira L, Mariotto AB,
Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel
RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J
Clin. 69:363–385. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hoffman PC, Mauer AM and Vokes EE: Lung
cancer. Lancet. 355:479–485. 2000.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Vinod SK: International patterns of
radiotherapy practice for non-small cell lung cancer. Semin Radiat
Oncol. 25:143–150. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Groth SS, Rueth NM, Hodges JS, Habermann
EB, Andrade RS, D'Cunha J and Maddaus MA: Conditional
cancer-specific versus cardiovascular-specific survival after
lobectomy for stage I non-small cell lung cancer. Ann Thorac Surg.
90:375–382. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Erdoes G, Basciani RM and Eberle B:
Etomidate-a review of robust evidence for its use in various
clinical scenarios. Acta Anaesthesiol Scand. 58:380–389.
2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fassnacht M, Hahner S, Beuschlein F, Klink
A, Reincke M and Allolio B: New mechanisms of adrenostatic
compounds in a human adrenocortical cancer cell line. Eur J Clin
Invest. 30 (Suppl 3):S76–S82. 2000.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chen HT, Zhou J, Fan YL, Lei CL, Li BJ,
Fan LX, Xu L, Xu M, Hu XQ and Yu ZY: Anesthetic agent etiomidate
induces apoptosis in N2a brain tumor cell line. Mol Med Rep.
18:3137–3142. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chu CN, Wu KC, Chung WS, Zheng LC, Juan
TK, Hsiao YT, Peng SF, Yang JL, Ma YS, Wu RS and Chung JG:
Etomidate suppresses invasion and migration of human A549 lung
adenocarcinoma cells. Anticancer Res. 39:215–223. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bernassola F, Karin M, Ciechanover A and
Melino G: The HECT family of E3 ubiquitin ligases: Multiple players
in cancer development. Cancer Cell. 14:10–21. 2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mokuda S, Nakamichi R, Matsuzaki T, Ito Y,
Sato T, Miyata K, Inui M, Olmer M, Sugiyama E, Lotz M and Asahara
H: Wwp2 maintains cartilage homeostasis through regulation of
Adamts5. Nat Commun. 10(2429)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhang R, Zhang J, Luo W, Luo Z and Shi S:
WWP2 is one promising novel oncogene. Pathol Oncol Res. 25:443–446.
2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ding ZY, Huang YJ, Tang JD, Li G, Jiang PQ
and Wu HT: Silencing of hypoxia-inducible factor-1α promotes
thyroid cancer cell apoptosis and inhibits invasion by
downregulating WWP2, WWP9, VEGF and VEGFR2. Exp Ther Med.
12:3735–3741. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yang R, He Y, Chen S, Lu X, Huang C and
Zhang G: Elevated expression of WWP2 in human lung adenocarcinoma
and its effect on migration and invasion. Biochem Biophys Res
Commun. 479:146–151. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Kuhn M, von Mering C, Campillos M, Jensen
LJ and Bork P: STITCH: Interaction networks of chemicals and
proteins. Nucleic Acids Res. 36 (Database Issue):D684–D688.
2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Liao XH, Lu DL, Wang N, Liu LY, Wang Y, Li
YQ, Yan TB, Sun XG, Hu P and Zhang TC: Estrogen receptor α mediates
proliferation of breast cancer MCF-7 cells via a
p21/PCNA/E2F1-dependent pathway. FEBS J. 281:927–942.
2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Dey N, De P and Leyland-Jones B:
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell
signaling to clinical trials. Pharmacol Ther. 175:91–106.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Gettinger S, Horn L, Jackman D, Spigel D,
Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC,
et al: Five-year follow-up of nivolumab in previously treated
advanced non-small-cell lung cancer: Results from the CA209-003
study. J Clin Oncol. 36:1675–1684. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Garon EB, Hellmann MD, Rizvi NA, Carcereny
E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L,
et al: Five-year overall survival for patients with advanced
non-small-cell lung cancer treated with pembrolizumab: Results from
the phase I KEYNOTE-001 study. J Clin Oncol. 37:2518–2527.
2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
McGrath M, Ma C and Raines DE:
Dimethoxy-etomidate: A nonhypnotic etomidate analog that potently
inhibits steroidogenesis. J Pharmacol Exp Ther. 364:229–237.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Forman SA: Clinical and molecular
pharmacology of etomidate. Anesthesiology. 114:695–707.
2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Av Sá LGD, Silva CRD, de A Neto JB,
Cândido TM, de Oliveira LC, do Nascimento FB, Barroso FD, da Silva
LJ, de Mesquita JR, de Moraes MO, et al: Etomidate inhibits the
growth of MRSA and exhibits synergism with oxacillin. Future
Microbiol. 15:1611–1619. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Liu J, Dong W, Wang T, Liu L, Zhan L, Shi
Y and Han J: Effects of etomidate and propofol on immune function
in patients with lung adenocarcinoma. Am J Transl Res. 8:5748–5755.
2016.PubMed/NCBI
|
|
27
|
Chantry A: WWP2 ubiquitin ligase and its
isoforms: New biological insight and promising disease targets.
Cell Cycle. 10:2437–2439. 2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Maddika S, Kavela S, Rani N, Palicharla
VR, Pokorny JL, Sarkaria JN and Chen J: WWP2 is an E3 ubiquitin
ligase for PTEN. Nat Cell Biol. 13:728–733. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
29
|
Wang K, Liu J, Zhao X, Li H, Luo G, Yu Y,
Guo Y, Zhang L, Zhu J, Wang S, et al: WWP2 regulates proliferation
of gastric cancer cells in a PTEN-dependent manner. Biochem Biophys
Res Commun. 521:652–659. 2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Dillon LM and Miller TW: Therapeutic
targeting of cancers with loss of PTEN function. Curr Drug Targets.
15:65–79. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Trigka EA, Levidou G, Saetta AA,
Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E,
Kavantzas N, Patsouris E and Korkolopoulou P: A detailed
immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung
cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational
status and clinicopathological features. Oncol Rep. 30:623–636.
2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Daniilidou K, Frangou-Plemenou M,
Grammatikakis J, Grigoriou O, Vitoratos N and Kondi-Pafiti A:
Prognostic significance and diagnostic value of PTEN and p53
expression in endometrial carcinoma. A retrospective
clinicopathological and immunohistochemical study. J BUON.
18:195–201. 2013.PubMed/NCBI
|
|
33
|
Pérez-Ramírez C, Cañadas-Garre M, Molina
MÁ, Faus-Dáder MJ and Calleja-Hernández MÁ: PTEN and PI3K/AKT in
non-small-cell lung cancer. Pharmacogenomics. 16:1843–1862.
2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Soond SM, Savvateeva LV, Makarov VA,
Gorokhovets NV, Townsend PA and Zamyatnin AA Jr: Making
connections: p53 and the cathepsin proteases as co-regulators of
cancer and apoptosis. Cancers (Basel). 12(3476)2020.PubMed/NCBI View Article : Google Scholar
|
